BIZARRE: 12 | Mind Blowing Facts

Clovis Shares Jumps After Highlighting Data From Targeted Radiotherapy Trial

Clovis Oncology Inc (NASDAQ:CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).  Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity, including a confirmed RECIST partial response in…

Benzinga · Jun 15, 2022

MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio

MorphoSys AG (NASDAQ:MOR) and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio is a biotechnology company based in South San Francisco that focuses on discovering and…

Benzinga · Jun 14, 2022

Belfast Pops Orchestra take on the Ulster Hall for children's cancer charity

Leader Stephen Cullen was inspired by his experience at the Children’s Haematology and Oncology Unit at the Royal

Belfast Live · Jun 14, 2022

Surface Oncology's Return On Capital Employed Overview

According to Benzinga Pro, during Q1, Surface Oncology (NASDAQ:SURF) earned $6.20 million, a 125.78% increase from the preceding quarter. Surface Oncology also posted a total of $30.00 million in sales, a 19380.52% increase since Q4.

Benzinga · Jun 3, 2022

5 Oncology Stocks Wall Street Predicts Will Rally 135% or More

The oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and the government should fuel the industry's growth. Given the industry's bright growth prospects, Wall Street analysts expect the stocks of quality oncology…

StockNews.com · May 31, 2022

Chennai hospital launches centre for geriatric oncology

It was inaugurated by senior geriatrician V.S. Natarajan

The Hindu · May 30, 2022

BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced interim Phase 1 data from healthy volunteers, supporting the development of BBP-671 for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias.  BBP-671 is being developed as a potential therapy for diseases in which coenzyme-A (CoA) metabolism is deficient, including PKAN, propionic acidemia (PA), and methylmalonic acidemia (MMA).…

Benzinga · May 26, 2022

Why Elevation Oncology Stock Is Rising

Elevation Oncology Inc (NASDAQ: ELEV) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions.

Benzinga · May 25, 2022

Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm

Citius Pharmaceuticals Inc (NASDAQ:CTXR) plans to form a new company (NewCo) focused on developing and commercializing I/ONTAK. A Phase 3 trial was completed in December 2021, and a biologics license application (BLA) is being planned for submission in the second half of 2022.  The Company's other pipeline assets, including Mino-Lok, would remain at…

Benzinga · May 25, 2022

Elevation Oncology Shares Gain On FDA Fast Track Designation For Seribantumab In Tumor-Agnostic Settings

Elevation Oncology, Inc. (NASDAQ: ELEV) received Fast Track designation from the Food and Drug Administration (FDA) for Seribantumab in tumor-agnostic settings for the treatment of advanced solid tumors that harbor NRG1 gene fusions.

Benzinga · May 25, 2022